250 related articles for article (PubMed ID: 32365798)
1. Male Breast Cancer: Results of the Application of Multigene Panel Testing to an Italian Cohort of Patients.
Tedaldi G; Tebaldi M; Zampiga V; Cangini I; Pirini F; Ferracci E; Danesi R; Arcangeli V; Ravegnani M; Martinelli G; Falcini F; Ulivi P; Calistri D
Diagnostics (Basel); 2020 Apr; 10(5):. PubMed ID: 32365798
[TBL] [Abstract][Full Text] [Related]
2. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of hereditary/familial breast cancer patients with multigene targeted next generation sequencing panel and MLPA analysis in Turkey.
Bora E; Caglayan AO; Koc A; Cankaya T; Ozkalayci H; Kocabey M; Kemer D; Aksoy S; Alicikus ZA; Akin IB; Durak MG; Gurel D; Yavuzsen T; Sevinc A; Somali I; Gorken I; Balci P; Karaoglu A; Saydam S; Ulgenalp A
Cancer Genet; 2022 Apr; 262-263():118-133. PubMed ID: 35220195
[TBL] [Abstract][Full Text] [Related]
4. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases.
Falchetti M; Lupi R; Rizzolo P; Ceccarelli K; Zanna I; Calò V; Tommasi S; Masala G; Paradiso A; Gulino A; Giannini G; Russo A; Palli D; Ottini L
Breast Cancer Res Treat; 2008 Jul; 110(1):161-7. PubMed ID: 17661168
[TBL] [Abstract][Full Text] [Related]
5. Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy.
Rizzolo P; Zelli V; Silvestri V; Valentini V; Zanna I; Bianchi S; Masala G; Spinelli AM; Tibiletti MG; Russo A; Varesco L; Giannini G; Capalbo C; Calistri D; Cortesi L; Viel A; Bonanni B; Azzollini J; Manoukian S; Montagna M; Peterlongo P; Radice P; Palli D; Ottini L
Int J Cancer; 2019 Jul; 145(2):390-400. PubMed ID: 30613976
[TBL] [Abstract][Full Text] [Related]
6. Male breast cancer risk associated with pathogenic variants in genes other than BRCA1/2: an Italian case-control study.
Bucalo A; Conti G; Valentini V; Capalbo C; Bruselles A; Tartaglia M; Bonanni B; Calistri D; Coppa A; Cortesi L; Giannini G; Gismondi V; Manoukian S; Manzella L; Montagna M; Peterlongo P; Radice P; Russo A; Tibiletti MG; Turchetti D; Viel A; Zanna I; Palli D; Silvestri V; Ottini L
Eur J Cancer; 2023 Jul; 188():183-191. PubMed ID: 37262986
[TBL] [Abstract][Full Text] [Related]
7. Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.
Tsaousis GN; Papadopoulou E; Apessos A; Agiannitopoulos K; Pepe G; Kampouri S; Diamantopoulos N; Floros T; Iosifidou R; Katopodi O; Koumarianou A; Markopoulos C; Papazisis K; Venizelos V; Xanthakis I; Xepapadakis G; Banu E; Eniu DT; Negru S; Stanculeanu DL; Ungureanu A; Ozmen V; Tansan S; Tekinel M; Yalcin S; Nasioulas G
BMC Cancer; 2019 Jun; 19(1):535. PubMed ID: 31159747
[TBL] [Abstract][Full Text] [Related]
8. Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results.
Pritzlaff M; Summerour P; McFarland R; Li S; Reineke P; Dolinsky JS; Goldgar DE; Shimelis H; Couch FJ; Chao EC; LaDuca H
Breast Cancer Res Treat; 2017 Feb; 161(3):575-586. PubMed ID: 28008555
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a Four-Gene Panel for Hereditary Cancer Risk Assessment.
Secondino A; Starnone F; Veneruso I; Di Tella MA; Conato S; De Angelis C; De Placido S; D'Argenio V
Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456488
[No Abstract] [Full Text] [Related]
10. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of Cancer Predisposition Germline Variants in Male Breast Cancer Patients: Results of the German Consortium for Hereditary Breast and Ovarian Cancer.
Rolfes M; Borde J; Möllenhoff K; Kayali M; Ernst C; Gehrig A; Sutter C; Ramser J; Niederacher D; Horváth J; Arnold N; Meindl A; Auber B; Rump A; Wang-Gohrke S; Ritter J; Hentschel J; Thiele H; Altmüller J; Nürnberg P; Rhiem K; Engel C; Wappenschmidt B; Schmutzler RK; Hahnen E; Hauke J
Cancers (Basel); 2022 Jul; 14(13):. PubMed ID: 35805063
[TBL] [Abstract][Full Text] [Related]
12. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE
Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246
[TBL] [Abstract][Full Text] [Related]
13. Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk.
Judkins T; Leclair B; Bowles K; Gutin N; Trost J; McCulloch J; Bhatnagar S; Murray A; Craft J; Wardell B; Bastian M; Mitchell J; Chen J; Tran T; Williams D; Potter J; Jammulapati S; Perry M; Morris B; Roa B; Timms K
BMC Cancer; 2015 Apr; 15():215. PubMed ID: 25886519
[TBL] [Abstract][Full Text] [Related]
14. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.
Francies FZ; Wainstein T; De Leeneer K; Cairns A; Murdoch M; Nietz S; Cubasch H; Poppe B; Van Maerken T; Crombez B; Coene I; Kerr R; Slabbert JP; Vral A; Krause A; Baeyens A; Claes KB
BMC Cancer; 2015 Nov; 15():912. PubMed ID: 26577449
[TBL] [Abstract][Full Text] [Related]
15. Identification of hereditary breast and ovarian cancer germline variants in Granada (Spain): NGS perspective.
Molina-Zayas M; Garrido-Navas C; García-Puche JL; Barwell J; Pedrinaci S; Atienza MM; García-Linares S; de Haro-Muñoz T; Lorente JA; Serrano MJ; Poyatos-Andújar A
Mol Genet Genomics; 2022 May; 297(3):859-871. PubMed ID: 35451682
[TBL] [Abstract][Full Text] [Related]
16. Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer.
Fostira F; Saloustros E; Apostolou P; Vagena A; Kalfakakou D; Mauri D; Tryfonopoulos D; Georgoulias V; Yannoukakos D; Fountzilas G; Konstantopoulou I
Breast Cancer Res Treat; 2018 May; 169(1):105-113. PubMed ID: 29335925
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer in East Africa: Prevalence and spectrum of germline SNV/indel and CNVs in BRCA1 and BRCA2 genes among breast cancer patients in Tanzania.
Rweyemamu LP; Gültaşlar BK; Akan G; Dharsee N; Namkinga LA; Lyantagaye SL; Yazıcı H; Atalar F
Cancer Med; 2023 Feb; 12(3):3395-3409. PubMed ID: 35908255
[TBL] [Abstract][Full Text] [Related]
18. Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2.
Kraus C; Hoyer J; Vasileiou G; Wunderle M; Lux MP; Fasching PA; Krumbiegel M; Uebe S; Reuter M; Beckmann MW; Reis A
Int J Cancer; 2017 Jan; 140(1):95-102. PubMed ID: 27616075
[TBL] [Abstract][Full Text] [Related]
19. Multigene Panel Sequencing Identifies a Novel Germline Mutation Profile in Male Breast Cancer Patients.
Al Saati A; Vande Perre P; Plenecassagnes J; Gilhodes J; Monselet N; Cabarrou B; Lignon N; Filleron T; Telly D; Perello-Lestrade E; Feillel V; Staub A; Martinez M; Chipoulet E; Collet G; Thomas F; Gladieff L; Toulas C
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762649
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions.
Su Y; Yao Q; Xu Y; Yu C; Zhang J; Wang Q; Li J; Shi D; Yu B; Zeng Y; Zhu X; Bai Q; Zhou X
Front Genet; 2021; 12():674094. PubMed ID: 34917121
[No Abstract] [Full Text] [Related]
[Next] [New Search]